Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery
Status:
Recruiting
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
Along with aging population, cancer incidence and mortality are increasing. However, despite
advances in oncology and surgery, long-term survival of cancer patients is far from optimal.
Dexmedetomidine is a highly selective alpha 2 adrenergic receptor agonist with sedative,
analgesic, and anxiolytic effects. Studies showed that perioperative use of dexmedetomidine
reduces delirium and some non-delirium complications after surgery. In long-term follow-up
studies of older patients who, for other reasons, were randomized to receive either
dexmedetomidine or placebo during intra- or postoperative period, dexmedetomidine use was
associated with improved long-term survival. This multicenter randomized trial aims to
investigate the effect of perioperative dexmedetomidine on long-term outcomes in older
patients undergoing cancer surgery.